HannahHamidehAsghariMD(She/Her)

Hematologic Oncology

Hematologist/Oncologist

Dr. Asghari is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
44151 15th St W
Ste 101
Lancaster, CA 93534
Phone+1 661-902-5600

Fax+1 661-951-0686

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2017 - 2020
Johns Hopkins UniversityResidency, Internal Medicine, 2014 - 2017
University of Florida College of MedicineClass of 2014

PubMed

Abstracts/Posters

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
Hannah Asghari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients _70 Years with Acute M...
Hannah H Asghari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation
Hannah H Asghari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
Hannah Asghari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (_60 Years Old) with Ac...
Hannah H Asghari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019